DMPK Talent Market Report 2026: What Hiring Leaders Should Know

DMPK Talent Market Report 2026

Based on Drug Metabolism and Pharmacokinetics (DMPK) openings tracked and analyzed by Hughes & Associates during the first half of 2026, several notable workforce trends are emerging across the pharmaceutical and biotechnology industries.

Our review included scientific and leadership positions ranging from Scientist to Vice President and Head of Function across both established pharmaceutical companies and clinical-stage biotechnology organizations. The analysis examined hiring demand, compensation disclosures, work models, therapeutic modalities, technical capability requirements, and leadership expectations within the DMPK function.

These observations provide a real-time view of how organizations are structuring teams, prioritizing capabilities, and competing for talent in an increasingly strategic area of drug discovery and development. 

Leadership Hiring Continues to Drive Demand

The DMPK market continues to show strong demand for experienced scientific leadership. While opportunities were available across the full career spectrum, more than half of the openings reviewed were at the Associate Director level or above.

Position LevelObserved Frequency
Scientist / Senior Scientist / Principal Scientist42.5%
Associate Director / Director / Senior Director37.5%
Executive Director / Vice President / Head of Function20.0%

Organizations increasingly appear to be seeking professionals capable of influencing discovery strategy, leading multidisciplinary project teams, and integrating DMPK into broader portfolio decisions.

Biotechnology Continues to Drive Hiring Activity

Biotechnology companies represented the majority of hiring activity throughout the year.

Company TypeObserved Frequency
Biotechnology & Specialty Biopharma82.5%
Large Pharmaceutical Companies17.5%

Many biotechnology organizations are expanding internal DMPK capabilities as programs advance from discovery through IND-enabling studies and into early clinical development. Several were also recruiting senior leaders to establish or grow DMPK functions while coordinating extensive external collaborations.

Oncology Remains the Most Active Therapeutic Area

Among the openings reviewed, oncology emerged as the most frequently represented therapeutic area.

Other commonly represented areas included:

  • Immunology & Inflammation
  • Neuroscience / CNS
  • Rare Disease
  • Gastrointestinal Disease
  • Hematology
  • Cardiometabolic Disease
  • Viral & Liver Disease
  • Ophthalmology

The continued growth of targeted therapies and precision medicine appears to be sustaining demand for DMPK expertise across increasingly complex drug development programs.

Multi-Modality Expertise Continues to Expand

Although small molecules remain the dominant therapeutic modality, employers are increasingly seeking DMPK professionals capable of supporting diverse platforms.

Therapeutic ModalityObserved Frequency
Small Molecules67.5%
Biologics / Large Molecules 40.0%
Peptides / Miniproteins17.5%
Oligonucleotides / RNA Therapeutics15.0%
Targeted Protein Degraders (TPD/PROTACs)12.5%
Antibody-Drug Conjugates (ADCs)12.5%
Gene Therapy7.5%
Radiopharmaceuticals5.0%

Percentages exceed 100% because many positions supported multiple therapeutic modalities.

Compared with just a few years ago, DMPK professionals are increasingly expected to apply the same scientific principles across multiple drug platforms, each with unique ADME, bioanalytical, and translational considerations.

Compensation Intelligence

Compensation remains highly competitive across the DMPK market.

Based on salary disclosures included within the reviewed postings:

Position LevelTypical Salary Range
Scientist – Principal Scientist$90K–$260K
Associate Director – Senior Director$164K–$338K
Executive Director / Vice President / Head$208K–$443K

Most organizations also referenced annual bonus programs, equity participation, long-term incentive plans, and comprehensive benefits packages, particularly among biotechnology companies.

Hybrid Work Remains Common, but Onsite Roles Continue to Be Important

Among positions that specified work arrangements, onsite work remained more common than seen in many other drug development disciplines.

Work ArrangementObserved Frequency
Onsite57.1%
Hybrid28.6%
Remote14.3%

Based only on positions that explicitly disclosed work arrangements.

Unlike many quantitative disciplines, DMPK continues to maintain a significant laboratory and cross-functional presence, contributing to the continued demand for onsite collaboration.

Scientific Capabilities in Highest Demand

Across the 40 openings reviewed, several capabilities appeared consistently.

CapabilityObserved Frequency
Pharmacokinetics100%
Cross-Functional Collaboration100%
ADME Expertise87.5%
Regulatory Support87.5%
PK / PK-PD Modeling80.0%
Human PK & First-in-Human Dose Prediction72.5%
CRO & External Partner Management70.0%
Bioanalysis & Data Interpretation45.0%
PBPK Modeling20.0%
AI / Machine Learning / AI-enabled Workflows17.5%

ADME Expertise Remains Foundational

Designing and interpreting ADME studies continues to form the foundation of modern DMPK practice.

Frequently requested expertise included:

  • Drug metabolism
  • Plasma protein binding
  • Drug-drug interaction assessment
  • Metabolite identification
  • Biotransformation
  • Tissue distribution
  • Permeability
  • In vitro and in vivo ADME studies

Organizations consistently sought candidates capable of translating ADME findings into meaningful project decisions rather than simply generating experimental data.

PK/PD Modeling Continues to Grow in Importance

PK and PK/PD modeling appeared across Scientist, Director, and executive-level roles.

Employers increasingly expect DMPK professionals to contribute to:

  • Human PK prediction
  • Dose projection
  • Exposure-response analysis
  • PBPK modeling
  • Mechanistic PK/PD modeling
  • Clinical translation
  • Sensitivity analyses
  • Virtual population simulations

Model-informed decision-making is becoming an increasingly common expectation across the broader DMPK function.

Translational Drug Development Is Now Central to DMPK

Many organizations now expect DMPK scientists to contribute throughout the drug development lifecycle.

Frequently referenced responsibilities included:

  • Candidate selection
  • Human PK prediction
  • First-in-human dose projection
  • Clinical risk assessment
  • Therapeutic index evaluation
  • Dose optimization
  • Translational strategy

The findings suggest that DMPK has evolved from a supporting discipline into an integral component of program strategy.

Regulatory Responsibilities Continue to Expand

Regulatory support appeared in 87.5% of the reviewed positions.

Frequently referenced activities included:

  • INDs
  • CTAs
  • NDAs
  • BLAs
  • Investigator Brochures
  • Common Technical Documents
  • Regulatory briefing packages
  • Responses to health authority questions

Senior-level positions frequently included direct interaction with regulatory agencies and responsibility for ensuring scientifically robust nonclinical packages.

CRO & External Partner Management

Management of CROs and external scientific partners appeared in 70.0% of the positions reviewed.

Common responsibilities included:

  • Vendor selection
  • Protocol development
  • Study oversight
  • Budget management
  • Timeline management
  • Scientific review
  • Bioanalytical oversight
  • Quality assurance

For many biotechnology companies, successful DMPK execution relies heavily on effective management of external scientific partnerships.

Bioanalysis Continues to Play a Critical Role

Bioanalysis remained an important component of many DMPK positions.

Frequently requested experience included:

  • LC-MS/MS
  • Ligand-binding assays
  • Assay development and validation
  • Metabolite identification
  • Biodistribution studies
  • Immunogenicity assessment
  • High-resolution mass spectrometry

The integration of bioanalysis with DMPK was particularly evident across biologics, peptide, ADC, radiopharmaceutical, and other emerging therapeutic modalities.

Leadership Expectations Continue to Expand

Today’s DMPK leaders are expected to contribute well beyond traditional ADME and pharmacokinetic responsibilities.

Common expectations included:

Strategic Leadership

  • Defining DMPK strategy
  • Influencing candidate selection
  • Supporting portfolio decisions
  • Identifying development risks
  • Guiding translational strategy

Matrix Leadership

Frequent collaboration with:

  • Medicinal Chemistry
  • Pharmacology
  • Toxicology
  • Clinical Pharmacology
  • Translational Medicine
  • Regulatory Affairs
  • Bioanalysis
  • Clinical Development
  • CMC
  • Modeling & Simulation

Organizational Leadership

Many senior positions also included:

  • Building DMPK teams
  • Developing scientific talent
  • Managing departmental budgets
  • Establishing external partnerships
  • Scaling internal capabilities

Emerging AI & Technology Signals

Artificial intelligence and digital technologies are beginning to influence DMPK hiring.

Among the reviewed positions, 17.5% referenced AI, machine learning, automation, or digital workflows.

Examples included:

  • AI-assisted modeling
  • Machine learning
  • Predictive ADME platforms
  • Automated DMPK workflows
  • Digital laboratory technologies

While still emerging, these capabilities are increasingly being incorporated alongside traditional experimental and quantitative approaches.

Key Takeaway

The 2026 DMPK talent market reflects the continued evolution of Drug Metabolism and Pharmacokinetics into a highly strategic function within modern drug discovery and development.

Organizations are increasingly seeking professionals who combine scientific depth in ADME and pharmacokinetics with quantitative modeling, translational thinking, regulatory expertise, and cross-functional leadership.

As therapeutic modalities continue to diversify and development programs become more complex, DMPK professionals are playing an increasingly influential role in candidate selection, dose optimization, clinical translation, and portfolio decision-making.

For hiring managers, HR leaders, and talent acquisition teams, the market continues to favor individuals who can integrate strong scientific expertise with broader strategic and organizational impact.

About Hughes & Associates

Keeping pace with today’s DMPK talent market requires ongoing visibility into hiring trends, organizational priorities, and emerging workforce needs.

At Hughes & Associates, we continuously monitor hiring activity, talent movement, compensation trends, and organizational developments across Clinical Pharmacology, Pharmacometrics, QSP, DMPK, Bioanalysis, and related translational sciences functions.

If your team is evaluating hiring strategy, workforce planning, organizational design, or simply looking to compare notes on what we are seeing across the market, we would be glad to connect for a confidential discussion.

To learn more about Hughes & Associates and our specialized life sciences search capabilities, visit our website: https://www.haallc.com

For additional market insights, industry updates, and talent trends, follow Hughes & Associates on LinkedIn, Instagram, Facebook, and X.

We look forward to continuing the conversation around the evolving DMPK and translational sciences talent landscape.

Read More

Clinical Pharmacology Talent Market Report 2026: What Hiring Leaders Should Know

Biopharma In A More Stable Phase: What It Means for Hiring and Careers in Clinical Pharmacology

Why Clinical Pharmacology Leadership Roles Are So Hard to Fill at the Director-to-Head Level


Leave a Reply

Your email address will not be published. Required fields are marked *

  • Home
  • About Us
  • Services
  • Career Opportunities
  • Blog
  • Podcast